Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Candel Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +3 vs. Q4 2021
- Shares held
- 6.67M
- −277.4K (−4.0%) vs. Q4 2021
- Total value
- $34.0M
- −$20.4M (−37.5%) vs. Q4 2021
- New holders
- 5
- 6 more added
- Sold out
- 2
- 6 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CADL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 137 | $518.9M |
| Q1 2026 | 114 | $212.9M |
| Q4 2025 | 84 | $133.5M |
| Q3 2025 | 81 | $115.6M |
| Q2 2025 | 78 | $116.6M |
| Q1 2025 | 82 | $119.7M |
| Q4 2024 | 71 | $155.7M |
| Q3 2024 | 52 | $46.4M |
| Q2 2024 | 45 | $37.0M |
| Q1 2024 | 20 | $5.97M |
| Q4 2023 | 22 | $5.92M |
| Q3 2023 | 20 | $4.86M |
| Q2 2023 | 20 | $6.77M |
| Q1 2023 | 21 | $7.44M |
| Q4 2022 | 21 | $9.70M |
| Q3 2022 | 25 | $19.1M |
| Q2 2022 | 23 | $20.6M |
| Q1 2022 | 23 | $34.0M |
| Q4 2021 | 20 | $54.4M |
| Q3 2021 | 12 | $52.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Candel Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 1,972,226 | $10.0M | 0.00% | −290,616−12.8% | Reduced |
| Northpond Ventures, LLC | 1,935,215 | $9.85M | 5.31% | 00.0% | Unchanged |
| Franklin Resources Inc | 1,125,000 | $5.73M | 0.00% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 811,737 | $4.13M | 0.86% | 00.0% | Unchanged |
| Vanguard Group Inc | 407,156 | $2.07M | 0.00% | −8,197−2.0% | Reduced |
| BlackRock Inc. | 132,322 | $674.0K | 0.00% | +17,708+15.5% | Added |
| Geode Capital Management, LLC | 75,217 | $382.0K | 0.00% | +16,932+29.1% | Added |
| Bridgeway Capital Management, LLC | 75,000 | $382.0K | 0.01% | +75,000 | New |
| 683 Capital Management, LLC | 40,929 | $208.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 27,600 | $140.0K | 0.00% | +1,000+3.8% | Added |
| Northern Trust Corp | 13,455 | $68.0K | 0.00% | 00.0% | Unchanged |
| Kestra Advisory Services, LLC | 12,500 | $64.0K | 0.00% | +12,500 | New |
| Empirical Asset Management, LLC | 12,000 | $61.0K | 0.06% | +12,000 | New |
| D. E. Shaw & Co., Inc. | 10,867 | $55.0K | 0.00% | +745+7.4% | Added |
| Goldman Sachs Group Inc | 10,510 | $53.0K | 0.00% | −83−0.8% | Reduced |
| Morgan Stanley | 4,651 | $24.0K | 0.00% | −71−1.5% | Reduced |
| JPMorgan Chase & Co | 3,387 | $17.0K | 0.00% | +858+33.9% | Added |
| UBS Group AG | 2,000 | $10.0K | 0.00% | −2,447−55.0% | Reduced |
| Bank of America Corp | 1,462 | $7.00K | 0.00% | +374+34.4% | Added |
| Citigroup Inc | 610 | $3.00K | 0.00% | −256−29.6% | Reduced |
| High Net Worth Advisory Group LLC | 300 | $2.00K | 0.00% | 00.0% | Unchanged |
| Quent Capital, LLC | 182 | $1.00K | 0.00% | +182 | New |
| Tower Research Capital LLC (TRC) | 54 | $0 | 0.00% | +54 | New |
| Woodline Partners LP | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −13,106−100.0% | Sold out |